Woman in a bright green sweater standing confidently against a purple background, next to text saying Aim Lower.

For people with extremely high triglycerides (TGs), such as those with Familial Chylomicronaemia Syndrome (FCS)

Lowering TGs to the ESC/EAS guideline level of ≤10 mmol/L (880 mg/dL) reduces the risk of acute pancreatitis1

Not an actual patient

Not an actual patient

FCS AND EXTREMELY HIGH TRIGLYCERIDES

This site is intended for EU healthcare professionals and explores Familial Chylomicronaemia Syndrome (FCS) – a rare condition that causes extremely high triglyceride levels and a range of complications2–4

People with extremely high triglycerides, above 10 mmol/L (880 mg/dL), who do not respond to conventional triglyceride-lowering approaches (e.g., fibrates, statins, and omega-3 fatty acids) may have a specific underlying aetiology. If their triglyceride levels do not lower enough with conventional approaches and lifestyle changes (e.g., a very low-fat diet and avoiding alcohol), consider an underlying cause such as FCS2–4

People with FCS can present with a variety of signs and symptoms, including:4

Abdominal pain

Eruptive xanthomas

Lipaemia retinalis

Fatigue

Acute pancreatitis

See the risk of acute pancreatitis

Acute pancreatitis is the most prevalent, severe, and potentially fatal complication that people with FCS face.5 Relative risk of acute pancreatitis is 14x greater in people with triglyceride levels above 10 mmol/L (880 mg/dL) compared to people with levels below 2.3 mmol/L (200 mg/dL)6Finding the underlying cause can help people access the right care to reduce their risk of acute pancreatitis7

If You See Extremely High Triglycerides

Rule out secondary causes8

Medical conditions

  • Diabetes
  • Kidney disease
  • Hypothyroidism
  • Autoimmune disease
  • Liver/storage disorders
  • Obesity
  • Pregnancy

Lifestyle factors

  • High-fat/high-sugar diet
  • Alcohol use
  • Inactivity
  • Parenteral nutrition

Medications

  • Steroids
  • Estrogens
  • Beta-blockers
  • Diuretics
  • Antipsychotics
  • HIV drugs
  • Chemotherapy
  • Immunosuppressants
  • Isotretinoin
  • Propofol

Then if triglyceride levels do not lower with conventional triglyceride-lowering approaches and lifestyle changes

Consider underlying causes such as FCS2,3,9

Two hikers trekking downward on a mountain trail with backpacks and a map, with purple gradient and arrow pointing down.

Elevated triglycerides

in people who appear otherwise healthy may point to underlying causes that standard approaches miss7

Not actual patients

AIM LOWER campaign headline in bold purple gradient text.

Endocrinology, cardiology, and lipidology experts agree that keeping triglyceride levels ≤10 mmol/L (880 mg/dL) reduces the risk of acute pancreatitis. The European Society of Cardiology and European Atherosclerosis Society (ESC/EAS) guidelines state that the risk of acute pancreatitis is clinically significant at triglyceride levels above 10 mmol/L (880mg/dL)1

Two-tone illustration of a chart on a downward trajectory.

Lower the risk of acute pancreatitis by referring early and aiming for guideline triglyceride levels1

When triglycerides stay high despite conventional approaches and lifestyle changes, why think FCS?

Find out more
Two-tone illustration of an open envelope.

Sign up for updates and more information

Receive further disease state information on FCS and its impact

Sign Up

Abbreviations

EAS, European Atherosclerosis Society; ESC, European Society of Cardiology; EU, European Union; FCS, Familial Chylomicronaemia Syndrome; HIV, Human Immunodeficiency Virus; TG, triglyceride.

Show References Expand Collapse

  1. Mach F, Baigent C, et al. Eur Heart J. 2020;41(1):111–88.
  2. Goldberg RB, Chait A, et al. Front Endocrinol (Lausanne). 2020;11:593931.
  3. Paragh G, Németh Á, et al. Lipids Health Dis. 2022;21:21.
  4. Davidson M, Stevenson M, et al. J Clin Lipidol. 2018;12(4):898–907.
  5. Gaudet D, Stevenson M, et al. Lipids Health Dis. 2020;19(1):120.
  6. Sanchez RJ, Ge W, et al. Lipids Health Dis. 2021;20(1):72.
  7. Falko JM. Endocr Pract. 2018;24(8):756–63.
  8. Virani SS, Morris PB, et al. J Am Coll Cardiol. 2021;78(9):960–93.
  9. Spagnuolo CM, Hegele RA, et al. Expert Rev Endocrinol Metab. 2024;19(4):299–306.

The site you are about to enter is intended for healthcare professionals only

I am a healthcare professional

Sign up for updates and more information

Sign Up